Neurocrine Biosciences
NBIX
NBIX
568 hedge funds and large institutions have $10.7B invested in Neurocrine Biosciences in 2024 Q3 according to their latest regulatory filings, with 68 funds opening new positions, 235 increasing their positions, 199 reducing their positions, and 85 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
568
Holders Change
-22
Holders Change %
-3.73%
% of All Funds
8.22%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.14%
New
68
Increased
235
Reduced
199
Closed
85
Calls
$79.4M
Puts
$74M
Net Calls
+$5.4M
Net Calls Change
-$66.4M
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$118M |
| 2 |
DM
Deerfield Management
New York
|
+$72.1M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$71.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$62.2M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$41.9M |
Top Sellers
| 1 |
JPMorgan Chase & Co
New York
|
-$99.6M |
| 2 |
AC
Armistice Capital
New York
|
-$91.8M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$74.5M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$68M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$66.7M |
